Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DVCN93
|
|||
| Drug Name |
INCAGN01949
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Advanced malignancy [ICD-11: 2A00-2F9Z] | Phase 2 | [1] | |
| Metastatic malignant neoplasm [ICD-11: 2D50-2E09] | Phase 2 | [1] | ||
| Company |
Agenis; Incyte
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | OX40L receptor (CD134) | Target Info | Agonist | [2] |
| KEGG Pathway | Cytokine-cytokine receptor interaction | |||
| NetPath Pathway | IL2 Signaling Pathway | |||
| Wnt Signaling Pathway | ||||
| Pathway Interaction Database | Downstream signaling in naï | |||
| Reactome | TNFs bind their physiological receptors | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02923349) A Phase 1/2, Open-Label, Dose-Escalation, Safety Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors. U.S. National Institutes of Health. | |||
| REF 2 | Sequential therapy with INCAGN01949 followed by ipilimumab and nivolumab in two patients with advanced ovarian carcinoma. Gynecol Oncol Rep. 2020 Oct 1;34:100655. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.